Search Filters:

The items contained in the list are being used to filter the search results. Click them to remove them from the search filter.
Displaying 41 - 60 of 943
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published Sort ascending
MHRA-102105-PIP01-25
  • Trontinemab
  • Treatment of Alzheimer's disease
  • Trontinemab
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101911-PIP01-25
  • Lunsekimig
  • Treatment of asthma
  • Pneumology - Allergology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-100606-PIP01-22-M02 (update)
  • SPARSENTAN
  • Treatment of focal segmental glomerulosclerosis
  • Filspari
  • Filspari
  • Filspari
  • Filspari
  • Other: Nephrology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101615-PIP01-24
  • ibuzatrelvir
  • Treatment of coronavirus disease 2019 (COVID-19)
  • Infectious diseases
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101376-PIP01-24
  • Frexalimab
  • Treatment of Type 1 Diabetes Mellitus
  • Endocrinology-Gynaecology-Fertility-metabolism
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101921-PIP01-25
  • quemliclustat
  • Treatment of pancreatic cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101826-PIP01-25
  • Orforglipron
  • Treatment of obesity
  • Not available at present
  • Endocrinology-Gynaecology-Fertility-metabolism
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Partial Compliance Check Granted
MHRA-100545-PIP01-22-M01 (update)
  • Lutetium (177Lu) edotreotide
  • Treatment of gastro-entero-pancreatic neuroendocrine tumours (GEP-NETs)
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101876-PIP01-25
  • rinatabart sesutecan
  • Treatment of endometrial cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101246-PIP01-23-M02 (update)
  • MEROPENEM
  • VABORBACTAM
  • Treatment of Gram-negative bacterial infections
  • Vaborem
  • Vabomere
  • Vaborem
  • Vabomere
  • Vaborem
  • Vabomere
  • Vabomere
  • Vaborem
  • Vaborem
  • Vaborem
  • Vaborem
  • Vaborem
  • Vabomere
  • Vaborem
  • Vaborem
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101955-PIP01-25
  • ARX517
  • Treatment of prostate cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101552-PIP01-24
  • litifilimab
  • Treatment of lupus erythematosus
  • Immunology -Rheumatology-Transplantation
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101319-PIP01-23-M02 (update)
  • denecimig
  • Treatment of haemophilia A
  • Haematology-Hemostaseology
PM: decision on the application for modification of an agreed paediatric investigation plan. Yes Full Compliance Check Granted
MHRA-101858-PIP01-25
  • atogepant
  • Treatment of migraine headaches
  • Aquipta
  • Aquipta
  • Neurology
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101174-PIP01-23
  • LENACAPAVIR SODIUM
  • Prevention of human immunodeficiency virus (HIV-1) infection
  • Sunlenca
  • Sunlenca
  • Infectious diseases
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) Yes Full Compliance Check Granted
MHRA-100268-PIP01-21-M04 (update)
  • INOTUZUMAB OZOGAMICIN
  • Treatment of acute lymphoblastic leukaemia
  • Besponsa
  • Haematology-Hemostaseology
  • Oncology
PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101941-PIP01-25
  • Velaprumig
  • Thyroid eye disease
  • Ophthamology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101855-PIP01-25
  • unasnemab
  • Treatment of Amyotrophic lateral sclerosis
  • Neurology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101866-PIP01-25
  • Humanised IgG1 monoclonal antibody against SEZ6 conjugated to a Top1 inhibitor
  • Treatment of small cell lung cancer
  • Oncology
W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100479-PIP01-22-M04 (update)
  • POSACONAZOLE
  • Prevention of invasive fungal infections
  • Treatment of invasive fungal infections
  • Noxafil
  • Noxafil
  • Noxafil
  • Noxafil
  • Noxafil
  • Noxafil
  • Noxafil
  • Noxafil
  • Infectious diseases
PM: decision on the application for modification of an agreed paediatric investigation plan. No